natalizumab
natalizumab is an intervention with 60 clinical trials. Currently 2 active trials ongoing. Historical success rate of 79.2%.
Success Metrics
Based on 42 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
14
Mid Stage
21
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
76.4%
42 of 55 finished
23.6%
13 ended early
2
trials recruiting
60
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
Clinical Trials (60)
Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants
Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis
Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma
Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study
A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants
A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration
Natalizumab Subcutaneous Immunogenicity and Safety Study
CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring
A Study for Tysabri Participant Preference
Inflammatory Response In Schizophrenia
Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
The 'Wearing Off' Effect of DMT
Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 60